GBA and Lysosomal Function in Parkinson's Disease describes a key molecular mechanism implicating glucocerebrosidase (GBA) in PD pathogenesis. GBA encodes the lysosomal enzyme glucocerebrosidase (GCase), which catalyzes the hydrolysis of glucosylceramide (GlcCer) to ceramide and glucose in the lysosome. Heterozygous GBA mutations represent the most common genetic risk factor for PD, increasing risk approximately 5-fold[1][2].
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, characterized clinically by rest tremor, bradykinesia, rigidity, and postural instability, and neuropathologically by loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the presence of Lewy bodies, which are primarily composed of the protein alpha-synuclein (alpha-synuclein). While the majority of PD cases are sporadic, about 5-10% are inherited, and among the known genetic risk factors, heterozygous mutations in the glucocerebrosidase gene (GBA) are the most frequent identified so far[3].
The discovery that GBA mutations increase PD risk 5-fold has spurred intense research into how a deficiency in a single lysosomal hydrolase can influence the aggregation, propagation, and clearance of alpha-synuclein, as well as broader lysosomal homeostasis. This article provides a comprehensive overview of the molecular mechanisms linking GBA and lysosomal function to PD pathogenesis, the clinical phenotype of GBA-associated PD (GBA-PD), and emerging therapeutic strategies aimed at restoring GCase activity or modulating downstream pathways.
These mutations are historically linked to Gaucher disease (GD), an autosomal recessive lysosomal storage disorder caused by biallelic GBA loss. Heterozygous carriers of GD-causing mutations have a higher prevalence of PD (up to 20-fold in some cohorts)[2:1]. Moreover, common non-coding variants near GBA have also been associated with sporadic PD.
GCase is central to the catabolism of glucosylceramide-derived lipids, influencing the composition of lipid rafts and the turnover of ceramide, a bioactive molecule involved in apoptosis, inflammation, and autophagy.
Elevated GlcCer can cause lysosomal membrane permeabilization (LMP), releasing cathepsins into the cytosol and triggering caspase-dependent cell death[7].
The exosome-mediated spread of alpha-synuclein seeds is enhanced in GBA-deficient cells, potentially explaining the more rapid disease progression observed clinically[10].
The GBA-LRRK2 interaction represents one of the most clinically significant gene-gene interactions in PD. Large-scale genetic studies have revealed that GBA mutation carriers who also carry LRRK2 G2019S variants exhibit a synergistic increase in PD risk and earlier age at onset. The mechanistic basis involves:
A bidirectional relationship exists where GCase deficiency promotes alpha-synuclein aggregation, and alpha-synuclein oligomers further inhibit GCase trafficking and activity[12]:
| Gene/Protein | Interaction with GBA | Functional Consequence |
|---|---|---|
| LRRK2 | GCase activity inversely correlates with LRRK2 kinase activity | Exacerbates synaptic vesicle trafficking deficits |
| SNCA (alpha-synuclein) | GCase deficiency promotes alpha-synuclein aggregation | Positive feedback loop |
| PARKIN & PINK1 | GBA loss impairs mitophagy | Enhanced oxidative stress |
| ATP13A2 | Co-deficiency leads to synergistic lysosomal alkalization | Further reduces autophagic flux[13] |
| SCARB2 (LIMP-2) | Mutations in SCARB2 impair GCase lysosomal delivery | Common pathway in lysosomal storage |
| Modality | GBA-Specific Finding |
|---|---|
| Cerebrospinal fluid (CSF) | Lower alpha-synuclein; elevated GlcCer |
| Blood | Increased plasma glucosylsphingosine (lyso-Gb1) - a sensitive biomarker of reduced GCase activity[17] |
| Neuroimaging | Reduced substantia nigra neuromelanin signal on MRI |
| Olfactory testing | Earlier olfactory dysfunction reported in GBA carriers |
| Target | Strategy | Status |
|---|---|---|
| Autophagy enhancement | mTOR inhibitors, TFEB overexpression | Pre-clinical |
| Alpha-synuclein immunotherapy | Active vaccines & passive antibodies | Phase II |
| Lysosomal acidification | Acidic nanoparticles | Pre-clinical |
| Neuroinflammation | Anti-inflammatory modulators | Phase I |
Aharon-Peretz J, et al. Glucocerebrosidase mutations in patients with Parkinson's disease. Neurology. 2004. ↩︎
Clark LN, et al. Mutations in the glucocerebrosidase gene increase risk for Parkinson's disease. Neurology. 2007. ↩︎ ↩︎
Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. Neurology. 2009. ↩︎
Mazzulli JR, et al. Glucocerebrosidase deficiency in dopaminergic neurons induces lysosomal dysfunction and alpha-synuclein aggregation. Cell. 2011. ↩︎ ↩︎
Sardi SP, et al. Glucosylceramide accumulation modulates synaptic function and proteostasis. J Clin Invest. 2017. ↩︎
Suzuki K, et al. Impaired autophagic flux in GBA-deficient neurons. Nat Neurosci. 2015. ↩︎
Hsieh JJ, et al. Lysosomal membrane permeabilization and cell death in GBA-deficient neurons. Cell Rep. 2021. ↩︎
Sun Y, et al. Cross-talk between GBA and other lysosomal hydrolases. Mol Cell. 2018. ↩︎
Avenali M, et al. CMA impairment in GBA-PD. Mov Disord. 2020. ↩︎
Schapira AH, et al. Exosome-mediated propagation of alpha-synuclein in GBA-deficiency. Neurology. 2019. ↩︎
Liu G, et al. LRRK2 kinase activity and GBA deficiency synergistically impair lysosomal trafficking. Nat Commun. 2021. ↩︎
Viswanathan R, et al. SNCA and GBA: a feed-forward loop in dopaminergic neurons. Brain. 2022. ↩︎
Wang H, et al. ATP13A2 deficiency exacerbates GBA-related lysosomal failure. Cell Rep Med. 2023. ↩︎
Iwaki H, et al. Cognitive decline and psychosis in GBA-PD. Neurology. 2020. ↩︎
Brockmann K, et al. Autonomic dysfunction in GBA mutation carriers. Neurology. 2021. ↩︎
Shepherd CE, et al. Neuroimaging signatures of GBA-PD. Neurology. 2021. ↩︎
Alcalay RN, et al. Plasma glucosylsphingosine as a biomarker of GCase activity. Neurology. 2020. ↩︎
McNeill A, et al. Ambroxol increases GCase activity in PD patients. Brain. 2022. ↩︎
Sardi SP, et al. Substrate reduction therapy with eliglustat in GBA-PD. Nat Med. 2023. ↩︎
Kuo SH, et al. AAV-GBA gene therapy in non-human primates. Nat Med. 2024. ↩︎
Zhang Y, et al. CRISPR correction of N370S in iPSC-derived neurons. Cell Stem Cell. 2024. ↩︎
Deng H, et al. Combination of ambroxol and venglustat in GBA-PD models. Sci Transl Med. 2023. ↩︎